PURPOSE: Combination of COL-3, a matrix metalloproteinase inhibitor, and doxorubicin (DOX) might be a promising anticancer regimen. The present study was to examine the potential pharmacokinetic interactions and toxicity profile following their coadministration in rats. METHODS: Normal rats were treated with single agent or different combinations with oral or intravenous COL-3 and DOX, and the bile-duct cannulated (BDC) rats received oral COL-3 plus DOX. In a separate disposition study, the effects of DOX on the biliary, urinary, and fecal excretion of COL-3 were examined. In addition, the effects of DOX on in vitro protein binding, metabolism, and transport of COL-3 across Caco-2 monolayers were investigated. RESULTS: COL-3 did not affect the pharmacokinetics of DOX in rats. However, treatment with DOX significantly decreased the oral absorption, and prolonged the elimination, of COL-3 in the normal rats, but not in the BDC rats. DOX did not alter the biliary and urinary excretion of COL-3, but significantly decreased the fecal excretion of COL-3. DOX significantly enhanced the basolateral to apical flux of COL-3 across Caco-2 monolayers, but had no apparent effects on the protein binding and metabolism of COL-3. The combination of DOX with oral COL-3 did not significantly (p > 0.05) increase the acute diarrhea score and intestinal damage compared to rats receiving DOX alone. CONCLUSIONS: These results indicated that DOX altered the oral absorption and elimination of COL-3, largely resulting from gastrointestinal toxicity caused by biliary excretion of DOX. Further studies are required to explore the efficacy and optimized dosage regimen of this promising combination.
PURPOSE: Combination of COL-3, a matrix metalloproteinase inhibitor, and doxorubicin (DOX) might be a promising anticancer regimen. The present study was to examine the potential pharmacokinetic interactions and toxicity profile following their coadministration in rats. METHODS: Normal rats were treated with single agent or different combinations with oral or intravenous COL-3 and DOX, and the bile-duct cannulated (BDC) rats received oral COL-3 plus DOX. In a separate disposition study, the effects of DOX on the biliary, urinary, and fecal excretion of COL-3 were examined. In addition, the effects of DOX on in vitro protein binding, metabolism, and transport of COL-3 across Caco-2 monolayers were investigated. RESULTS: COL-3 did not affect the pharmacokinetics of DOX in rats. However, treatment with DOX significantly decreased the oral absorption, and prolonged the elimination, of COL-3 in the normal rats, but not in the BDC rats. DOX did not alter the biliary and urinary excretion of COL-3, but significantly decreased the fecal excretion of COL-3. DOX significantly enhanced the basolateral to apical flux of COL-3 across Caco-2 monolayers, but had no apparent effects on the protein binding and metabolism of COL-3. The combination of DOX with oral COL-3 did not significantly (p > 0.05) increase the acute diarrhea score and intestinal damage compared to rats receiving DOX alone. CONCLUSIONS: These results indicated that DOX altered the oral absorption and elimination of COL-3, largely resulting from gastrointestinal toxicity caused by biliary excretion of DOX. Further studies are required to explore the efficacy and optimized dosage regimen of this promising combination.
Authors: M A Rudek; W D Figg; V Dyer; W Dahut; M L Turner; S M Steinberg; D J Liewehr; D R Kohler; J M Pluda; E Reed Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: D R Shalinsky; J Brekken; H Zou; L A Bloom; C D McDermott; S Zook; N M Varki; K Appelt Journal: Clin Cancer Res Date: 1999-07 Impact factor: 12.531
Authors: D R Shalinsky; J Brekken; H Zou; C D McDermott; P Forsyth; D Edwards; S Margosiak; S Bender; G Truitt; A Wood; N M Varki; K Appelt Journal: Ann N Y Acad Sci Date: 1999-06-30 Impact factor: 5.691
Authors: Mary Cianfrocca; Timothy P Cooley; Jeannette Y Lee; Michelle A Rudek; David T Scadden; Lee Ratner; James M Pluda; William D Figg; Susan E Krown; Bruce J Dezube Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Jean-Yves Douillard; Christian Peschel; Frances Shepherd; Luis Paz-Ares; Andrew Arnold; Mary Davis; Maurizio Tonato; Michael Smylie; Dongsheng Tu; Maurizio Voi; Jeffrey Humphrey; Jon Ottaway; Katherine Young; Anne Van Vreckem; Lesley Seymour Journal: Lung Cancer Date: 2004-12 Impact factor: 5.705
Authors: Jamee Martin; Scott C Howard; Asha Pillai; Peter Vogel; Anjaparavanda P Naren; Steven Davis; Karen Ringwald-Smith; Karyl Buddington; Randal K Buddington Journal: Chemotherapy Date: 2014-10-21 Impact factor: 2.544